| Latest Sangamo Biosciences News Headlines | | Date | Time | Source | | | 2009/10/14 | 00 : 30 | PRNUS | Sangamo Announces Closing of Common Stock Offering
RICHMOND, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock at a price of $7.20 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting... More...>> |
| 2009/10/07 | 21 : 15 | PRNUS | Sangamo Announces Pricing of Public Offering of Common Stock
RICHMOND, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced the pricing of a public offering of 3,000,000 shares of its common stock. The offering is expected to close on or about October 13, 2009, subject to the satisfaction of customary closing conditions. In addition... More...>> |
| 2009/09/29 | 04 : 05 | PRNUS | Sangamo BioSciences Announces Presentation at the JMP Securities Healthcare Conference
RICHMOND, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:30 am ET... More...>> |
| 2009/09/23 | 19 : 00 | PRNUS | Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Expansion of Program Will Test Repeat Dosing Protocol of SB-728-T
RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label... More...>> |
| 2009/09/17 | 04 : 05 | PRNUS | Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
RICHMOND, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 1:30 pm ET... More...>> |
| 2009/07/24 | 02 : 00 | PRNUS | Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
A breakthrough in transgenic animal production enables development of new human disease models
MILWAUKEE, RICHMOND, Calif., ST LOUIS, PALO ALTO, Calif., and PARIS, July
23 /PRNewswire-FirstCall/ -- Scientists from The Medical College of Wisconsin in Milwaukee, Sangamo Biosciences, Inc., (NASDAQ:SGMO), Sigma-Aldrich Corporation... More...>> |
| 2009/06/08 | 19 : 00 | PRNUS | Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints
RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today the presentation of as yet unreleased positive Phase 2... More...>> |
| 2009/06/04 | 04 : 05 | PRNUS | Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
RICHMOND, Calif., June 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 11:30 am ET... More...>> |
| 2009/05/14 | 04 : 05 | PRNUS | Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
RICHMOND, Calif., May 13 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 10:00 am PT... More...>> |
| 2009/05/04 | 22 : 05 | PRNUS | Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
RICHMOND, Calif., May 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO), the world leader in the research and development of zinc finger DNA-binding proteins (ZFPs), announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The... More...>> |
| 2009/04/30 | 04 : 05 | PRNUS | Sangamo BioSciences Reports First Quarter 2009 Financial Results
RICHMOND, Calif., April 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today reported first quarter 2009 financial results and accomplishments.
For the first quarter ended March 31, 2009, Sangamo reported a consolidated net loss of $6.8 million, or $0.17 per share, compared to a net loss of $8.0... More...>> |
| 2009/04/30 | 01 : 05 | PRNUS | Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking i
RICHMOND, Calif., April 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today continued success of its zinc finger DNA-binding protein (ZFP) technology. New research published in the scientific journal Nature by licensing partner Dow AgroSciences and Sangamo demonstrated the successful... More...>> |
| 2009/04/23 | 04 : 05 | PRNUS | Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
RICHMOND, Calif., April 22 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that the company will release its first quarter 2009 financial results on Wednesday, April 29, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will... More...>> |
| 2009/03/04 | 05 : 05 | PRNUS | Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at two investor... More...>> |
| 2009/02/05 | 05 : 05 | PRNUS | Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Company Ends Year with Cash and Investments of $65.0 Million
RICHMOND, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today reported fourth quarter and full year 2008 financial results and accomplishments and provided an outlook for 2009.
For the fourth quarter ended December 31, 2008... More...>> |
| 2009/02/03 | 20 : 00 | PRNUS | Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Therapeutic Approach Provides HIV-Resistant Immune Cells
RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS.
Based... More...>> |
| 2009/01/29 | 05 : 15 | PRNUS | Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
RICHMOND, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced that the company will release its fourth quarter and year-end 2008 financial results on Wednesday, February 4, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m... More...>> |
| 2009/01/12 | 20 : 00 | PRNUS | Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
Milestone Achieved A Year Ahead of Schedule
ST. LOUIS and RICHMOND, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) today announced it has reached a major production capacity milestone as part of its agreement with Sigma-Aldrich Corporation (NASDAQ:SIAL) to commercialize zinc finger... More...>> |
| 2009/01/06 | 05 : 05 | PRNUS | Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
RICHMOND, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 2:00 pm (PT) on... More...>> |
| 2008/12/22 | 20 : 00 | PRNUS | Sangamo BioSciences Announces License Agreement With Pfizer for Zinc Finger Nucleases for Protein Production
License Permits Use of ZFN Reagents to Knock Out Gene in Protein Production Cells
RICHMOND, Calif., Dec. 22 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO), the leading developer of zinc finger DNA-binding proteins (ZFPs), today announced an agreement to provide Pfizer Inc (NYSE:PFE) with a worldwide... More...>> |
|